



**CBI** CLAL  
BIOTECHNOLOGY  
INDUSTRIES  
(TASE: CBI)

**CORPORATE PRESENTATION**  
OCTOBER 2021

# DISCLAIMER

This presentation contains forward-looking statements within the meaning of the Israeli securities law that involve risks and uncertainties. These forward-looking statements relating to future events and future performance of the Company and the portfolio companies, jointly or separately, such as statements regarding, but are not limited to, market opportunities, strategy, competition, the further development and potential safety and efficacy of the products, the projected revenue and expense levels and the adequacy of the available cash resources. Some of the information contained herein is based upon or derived from information provided by third-party consultants and other industry sources as well as by the portfolio companies. We have not independently verified and cannot assure the accuracy of any data obtained by or from these sources.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements to be materially different than expressed or implied by these forward-looking statements. Drug discovery and development involve a high degree of risk. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are in some cases beyond our control and which could materially affect actual results, level of activity, performance or achievements. These risks and other factors include, among others, risks relating to: the successful preclinical development of the product candidates; the completion of clinical trials; the successful completion of the regulatory process with the FDA and other regulatory bodies, including the FDA's review of any filings the portfolio companies make in connection with treatment protocols; uncertainties related to the ability to attract and retain partners for the technologies and products under development; infringement of the intellectual property; market penetration of competing products; raising sufficient funds needed to support the research and development efforts, and other factors described in our public filings, including the recent Annual Report. These factors are updated from time to time through the filing of periodic and immediate statements with the Israel Securities Authority. Any forward-looking statements contained in this presentation are made as of the presentation date and the Company is under no obligation to revise or update these forward-looking statements.

Although we believe that the expectations reflected in these forward-looking statements are based upon reasonable assumptions, no assurance can be given that such expectations will be attained or that any deviations will not be material. No reliance may be placed for any purpose whatsoever on the information contained in this presentation or on its completeness. No representation or warranty, express or implied, is given by us or on our behalf and/or our portfolio companies or any of our directors, officers or employees or any other person as to the accuracy or completeness of the information or opinions contained in this presentation. Neither we nor any of our portfolio companies, directors, officers, employees or any other person accept any liability, whatsoever, for any loss howsoever arising, directly or indirectly, from any use of such information or opinions or otherwise arising in connection therewith.

The Company is continuously monitoring the impact of the worldwide spread of the corona virus (COVID-19) on its activities and the activities of its portfolio companies. At this time, there is a material uncertainty regarding the economic and other ramifications of the spread of COVID-19. This spread might have a negative effect on the activities of the Company and its portfolio companies, including, but not limited to, their market value, the ability to raise capital (governmental, private or public), the ability to materialize the Company's holdings, the possibility to advance strategic transactions, and the ability to carry out R&D and regulatory activities.

This presentation does not constitute or form part of, and should not be construed as constituting or forming part of, any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any of the Company shares or its portfolio companies shares, nor shall any part of this presentation nor the fact of its distribution form part of or be relied on in connection with any contract or investment decision relating thereto, nor does it constitute a recommendation regarding our or our portfolio companies securities.

# INVESTMENT OPPORTUNITIES IN HEALTHCARE

## Large and Growing Industry

- Revenues > \$1.3 trillion
- High profit margins, strong cash-flows, significant multiples
- Resistant to economic cycles
- Multiple opportunities



## Investment Approach

- Transatlantic deal sourcing
- Active lead/co-lead investor
- Long-term investment expertise
- Exit-driven investments

## Compelling Exit Markets


- Attractive M&A environment
- Cash-rich corporate acquirers
- Significant premiums
- IPOs: tangible exit option

# CLAL BIOTECHNOLOGY INDUSTRIES

Leading, publicly traded, life sciences investment company (TASE: CBI)




A member of Len Blavatnik's Access Industries group



Team and portfolio based in Tel Aviv and Boston



## Shareholders



Collaborations with global healthcare companies and major investment funds



Portfolio of well-funded biotech/ med-tech companies; ~\$300M raised in 2020/2021



Advanced technologies from leading US & IL institutions addressing major unmet needs



# PERFORMANCE IN 2020/ 2021

Cadent acquired  
by Novartis for  
**\$210-770M**



Neon acquired  
by BioNTech for  
**\$67M**



**\$300M** raised  
by portfolio  
companies

NIS **36M** dividend  
and up to NIS **10M**  
buyback us underway

Positive phase 3  
readouts



BLA submission



SCIENCE ADVANCES | RESEARCH ARTICLE

CORONAVIRUS

## A lymph node-targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2

Martin P. Steinbuck, Lochana M. Seenappa, Aniela Jakubowski, Lisa K. McNeil, Christopher M. Haqq\*, Peter C. DeMuth

The profound consequences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mandate urgent development of effective vaccines. Here, we evaluated an Amphiphile (AMP) vaccine adjuvant, AMP-CpG, composed of diacyl lipid-modified CpG, admixed with the SARS-CoV-2 Spike-2 receptor binding domain protein as a candidate vaccine (ELI-005) in mice. AMP modification efficiently delivers CpG to lymph nodes, where innate and

Critical Care  
Explorations

Brief Report

## EP-7041, a Factor XIa Inhibitor as a Potential Antithrombotic Strategy in Extracorporeal Membrane Oxygenation: A Brief Report

Charles V. Pollack, Jr. MA, MD<sup>1,2</sup>; Michael A. Kurz, PhD<sup>2</sup>; Neil J. Hayward, PhD<sup>2</sup>

Received: 17 October 2020 | Revised: 1 June 2021 | Accepted: 15 June 2021  
DOI: 10.1111/wrr.12958

ORIGINAL RESEARCH - CLINICAL SCIENCE

Wiley

## Bromelain-based enzymatic debridement of chronic wounds: Results of a multicentre randomized controlled trial

Yaron Shoham MD<sup>1,2</sup> | Eyal Shapira MD<sup>3</sup> | Josef Haik MD<sup>4,5</sup> |  
Moti Harats MD<sup>4,5,6,7</sup> | Dana Egozi MD PhD<sup>8,9</sup> | Dror Robinson MD<sup>5,10</sup> |  
Leonid Kogan MD PhD<sup>11</sup> | Rania Elkhatib MD<sup>12</sup> | Geza Telek MD PhD<sup>13</sup> |  
Avshalom Shalom MD<sup>14</sup>

applied  
sciences

MDPI

Article

## Efficiency of Bromelain-Enriched Enzyme Mixture (NexoBrid™) in the Treatment of Burn Wounds

Mihaela Pertea<sup>1,2</sup>, Vladimir Poroch<sup>1,3,\*</sup>, Petru Ciobanu<sup>1,2,\*</sup>, Alexandru Filip<sup>1,4</sup>, Natalia Velenciuc<sup>1,5</sup>, Sorinel Lunca<sup>1,5</sup>, Andrian Panuta<sup>1,2</sup>, Mihaela Buna-Arvinte<sup>1,6</sup>, Stefana Luca<sup>1</sup> and Bogdan Veliceasa<sup>1,4</sup>

blood

Available online 24 June 2021  
In Press - Journal Pre-proof

## Omidubicel Versus Standard Myeloablative Umbilical Cord Blood Transplantation: Results of a Phase III Randomized Study

Mitchell E. Horwitz<sup>1</sup>, Patrick J. Stiff<sup>2</sup>, Corey Cutler<sup>3</sup>, Claudio Brunstein<sup>4</sup>, Rabi Hanna<sup>5</sup>, Richard T. Maziarz<sup>6</sup>, Andrew R. Rezvani<sup>7</sup>, Nicole A. Karris<sup>8</sup>, Joseph McGuirk<sup>9</sup>, David Valcarcel<sup>10</sup>, Gary J. Schiller<sup>11</sup>, Caroline A. Lindemans<sup>12</sup>, William YK Hwang<sup>13</sup>, Liang Piu Koh<sup>14</sup>, Amy Keating<sup>15</sup>, Yasser Khaled<sup>16</sup>, Nelson Hamerschlag<sup>17</sup>, Olga Frankfurt<sup>18</sup> ... Guillermo Sanz<sup>22</sup>


# DIVERSE CLINICAL DEVELOPMENT ACTIVITY




- Biopharma
- Med-tech, direct and indirect holdings through the Anatomy VC fund (50% held by CBI)
- Acquired by Novartis. CBI is entitled to additional \$65M in contingent considerations

# BALANCED AND DIVERSIFIED PORTFOLIO


Stage of Development



Asset Distribution



Therapeutic Areas









# VALUE CREATION OVER THE YEARS

		2018	2019	2020/2021
<b>IPO</b>	3 IPOs on Nasdaq	Neon	Anchiano	Pi Cardia
<b>Pharma</b>	5 strategic deals	Gamida Cell	MediWound	Neon
		Neon	eXIthera	Cadent
		Biokine	Colospan	Anchiano
		Elicio	Gamida Cell	FDNA
<b>M&amp;A</b>	3 M&As	Cadent	Sight Diagnostics	Pi Cardia
		eXIthera		Sight Diagnostics
<b>Financing</b>	~\$700 million raised			Gamida Cell
				Elicio












# MULTIPLE NEAR-TERM PIPELINE CATALYSTS

## H1 2021

- ✓ ELI-002 phase 1/2 trial initiation 
- ✓ Motixafortide phase 3 trial readout 
- ✓ Anchiano – Chemomab merger 
- ✓ MWPC005 phase 1/2 trial initiation 
- ✓ OLO US launch 
- ✓ First Shortcut™ procedures in humans 

## H2 2021


- Omidubicel BLA submission 
- NexoBrid FDA approval 
- GDA-201 IND submission 
- MIJ-821 phase 2 trial readout 
- SPAC IPO on Nasdaq 
- EP-7041 phase 2 trial initiation 
- ✓ EscharEx phase 2 trial interim data 
- MWPC005 phase 1/2 trial readout 
- Elicio IPO on Nasdaq 

---

# **PORTFOLIO HIGHLIGHTS**

## Potent next generation, lymph node-targeting, immuno-modulatory therapeutic and prophylactic vaccines for cancer and infectious diseases

- Lymph node targeting aims to achieve potent immune activation, robust T cell response, immune memory, and, in cancer, tumor durable eradication
- Solid intellectual property; ongoing relationship with founding MIT laboratory
- ELI-002: anti-mKRAS therapeutic vaccine for pancreatic and colorectal cancers with KRAS mutations; a phase 1b trial started in Q2 2021, initial data expected in H1 2022
- Pipeline includes combination therapy with CAR-T for better efficacy in solid tumors
- Preclinical data from Elicio's COVID-19 vaccine indicate:
  - Up to 25-fold more T cell response over benchmark vaccines and >265-fold greater neutralizing antibody levels than recovering patients
  - Potent CD8 and CD4 T cell presence in lung tissue and respiratory fluid



*Science. 2019, 12; 365(6449): 162-168*

Lymph node targeting better unlocks the power of the immune response



## Develops, manufactures & commercializes drugs for burns and wound care

### NexoBrid - an enzymatic orphan drug for burn debridement


- Marketed in the EU and other territories; becoming standard of care
- Phase 3 trial for FDA approval has met the primary and all secondary endpoints; BLA submission is being prepared following FDA comments
- Strategic agreements of up to \$202 million with BARDA: funding R&D activities and procuring NexoBrid for \$16.5 million
- License agreement with Vericel (Nasdaq: VCEL) for NexoBrid in North America

### EscharEx - an enzymatic drug for chronic wound debridement


- Positive results in initial phase 2 trial
- A large phase 2 trial of EscharEx vs. standard of care in venous leg ulcers initiated; successful interim assessment in Q2 2021

### MWPC005 - a topical treatment for Basal Cell Carcinoma

- Currently in 2 Phase 2 trials, initial data expected towards YE 2021




**Kaplan-Meier estimates for time to complete eschar removal**



Evidence-based breakthrough technology addressing large and growing markets

NASDAQ: MDWD




## World leader in developing novel, safer, first-in-class antithrombotic drugs

- Despite the benefits of available anticoagulants, all have significant bleeding risk
- Factor XI antagonists inhibit the intrinsic clotting pathway, related to cardiovascular risk, not the extrinsic pathway, critical to bleeding control in surgery and trauma
- Humans with genetically low levels of factor XI have decreased incidence of thrombosis, without associated spontaneous bleeding

## EP-7041 - a novel, IV, selective small molecule Factor XIa inhibitor

- Phase 1 trial in healthy volunteers showed good tolerance, predictable dose-dependent increase in aPTT (efficacy marker) and rapid start and end of activity
- Strategic collaboration with Haisco Pharmaceutical Group (002653:CH)
- Phase 2 trial evaluating EP-7041 in COVID-19 patients in ICU is expected to start in Q4 2021, and a trial in the setting of extracorporeal circulation (e.g., ECMO) is also being planned

Phase 1 trial coagulation data



Factor XIa inhibition may finally dissociate anti-thrombotic effect from bleeding risk

## Unique technology for cellular expansion


**Omidubicel** – cord blood-derived stem cell therapy for hematological malignancies

- Orphan drug status and ‘Breakthrough Therapy’ designation granted by FDA
- Phase 3 trial (n=125) completed; BLA submission planned for Q4 2021
  - **Primary endpoint of neutrophil engraftment achieved**, with median time to engraftment of 12 days in the omidubicel group vs. 22 days in the comparator group (p<0.001)
  - **Trial met all 3 secondary endpoints** (day 42 platelet engraftment, Grade 2/3 infections by day 100 post-transplant, days alive out of the hospital by day 100 post-transplant)

**GDA-201** – NK cell-based therapy; phase 1 trial in hematological malignancies is ongoing; promising early evidence of clinical activity observed in advanced non-Hodgkin’s lymphoma

- Additional NK cell programs in pre-clinical development

## Phase 3 trial primary endpoint: cumulative incidence of neutrophil engraftment



NASDAQ: GMDA




Omidubicel is designed to enhance the life-saving benefits of cord blood stem cell transplant

---

# SUMMARY


# REASONS TO INVEST IN CBI







# EXPERIENCED MANAGEMENT TEAM

Transatlantic well-connected team with sound scientific, medical, and commercial expertise



**Avi Fischer - Chairman of the Board**



**claltech**



**William Koster, PhD**



**Neurogen Corporation**



**SciFluor**



**Bristol-Myers Squibb**



**Robert Connelly  
Strategic Advisor**



**domantis**




**axcella**




**pulmatrix**




**FLAGSHIP PIONEERING  
SCIENTIFIC VENTURES FOR LIFE**




**Ofer Gonen - CEO**



**gamida Cell**



**MediWound**



**Emi**



**Assaf Segal - CFO**



**MediWound**



**pwc**



**amdocs**



**Variance**



**Gilad Rosenberg, MD -  
Medical Director**



**PHARM**



**MSD**

# YOUR CONTACT

Clal Biotechnology Industries Ltd.



3 Azrieli Center  
Triangle Tower, 45th floor  
132 Menachem Begin  
Tel Aviv, 6701101  
Israel



Phone: +972 3 6121616



[office@cbi.co.il](mailto:office@cbi.co.il)



[www.cbi.co.il](http://www.cbi.co.il)